# A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.

> **NCT01727141** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 1042 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** QVA149
- **DRUG:** QAB149
- **DRUG:** NVA237
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01727141
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 1042 (ACTUAL)
- **Last updated:** 2016-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01727141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01727141, "A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01727141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*